CompletedPhase 2NCT00884286
Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
Studying Adult T-cell leukemia/lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PharmaMar
- Principal Investigator
- Vincent Ribrag, MDInstitut Gustave Roussy, France
- Intervention
- Aplidin®(drug)
- Enrollment
- 67 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004 – 2010
Study locations (12)
- Centre Hospitalier Lyon Sud, Lyon, France
- Hôpital Saint- Louis, Paris, France
- Institut Gustave Roussy, Villejuif, France
- Istituto di ematologia e oncologia medica "L. e. A. Seragnoli", Bologna, Italy
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Ospedaliero Universitaria de Modena, Modena, Italy
- Instituto Nacional de Enfermedades Neoplásicas (INEN), Surquillo, Lima region, Peru
- Hospital Español Auxilio Mutuo de Puerto Rico Inc., San Juan, Puerto Rico
- Hospital Clinico de Barcelona, Barcelona, Spain
- Hospital Morales Meseguer, Murcia, Spain
- Hospital Universitario de Salamanca, Salamanca, Spain
- Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni, Bellinzona, Switzerland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00884286 on ClinicalTrials.govOther trials for Adult T-cell leukemia/lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05745714HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE2NCT07159620Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07108868A Phase I Dose Finding Study of MB-CART2219.1University Hospital Tuebingen
- RECRUITINGNCT05237986Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell TherapyNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT07008885BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALLChinese PLA General Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT07541755PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALLFujian Medical University Union Hospital
- RECRUITINGPHASE2NCT06698003A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT06598722BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine